Standard & Poor’s Global Ratings last week said it believes that recent payment cuts to not-for-profit hospitals under the 340B drug savings program “will likely weaken their operating performance at a time of already tightening margins.” The report notes that the cuts “could lead to negative rating actions if hospital-specific funding reductions were material and not offset by other management actions. And despite the possibility of a legal challenge to the cuts, additional proposed program reforms at the federal level could further negatively affect these providers' finances.” A federal appeals court earlier this month heard oral arguments in a case brought by the AHA, Association of American Medical Colleges, America’s Essential Hospitals and three hospital organizations to challenge a nearly 30% reduction to Medicare payments for 340B drugs. The AHA hopes for a ruling from the court sometime this summer.

Related News Articles

Headline
The AHA and other plaintiffs late Friday asked a federal district judge to set a firm June deadline for the Department of Health and Human Services to propose…
Headline
A federal district court judge yesterday ruled that the Department of Health and Human Services would get "first crack at crafting appropriate remedial…
Headline
The Health Resources and Services Administration today launched a new website that organizations participating in the 340B Drug Pricing Program can use to…
Insights and Analysis
As the 2019 chair of the AHA’s Section for Small or Rural Hospitals, I can attest that AHA is stepping up in a big way to grapple with the issues that affect…
Headline
A federal court should order the Department of Health and Human Services to "make whole" 340B hospitals that received reimbursement reductions resulting from…
Headline
A federal court should order the Department of Health and Human Services to “make whole” 340B hospitals that received reimbursement reductions resulting from…